B cells & MS: see the clinical connection
B Cells & MS: See the clinical connection
Multiple sclerosis (MS) is characterised by ongoing disease activity, both clinical and subclinical, which can predict future disability and lead to permanent damage.1,2,3
Subclinical disease activity, which is revealed by MS lesions, may be assessed by magnetic resonance imaging (MRI). MS-associated lesions are a result of demyelination caused by lymphocytes, including B cells.4,5
B cells are important drivers of ongoing disease activity in MS.4,6
B Cells are Present in MS
B cells are largely present in the central nervous system (CNS) of patients with MS, but are largely absent from the CNS of healthy controls.7,8
B cells are drivers of disease progression in MS
- Demyelination lesions are a hallmark of disease activity in MS9
- A CNS lesion is commonly characterised by indefinite margins, demyelination, and notably dense populations of many types of immune cells around a blood vessel, including T and B cells9
- The appearance of new lesions can significantly increase the risk of disability progression, even in the absence of clinical relapses1
- Relapsing-remitting MS (RRMS) phenotypes can be described as either active or not active, with active disease characterised by MRI activity and/or clinical relapses10
- In RRMS, MRI scans usually reveal multiple small periventricular lesions, resulting from focal inflammation5,11
- CD20+ B cells are frequently found in the cerebrospinal fluid (CSF) of patients with all forms of MS.6 In patients with RRMS, elevated B-cell levels in the CSF correlate with an enhanced disease progression rate7
- Primary progressive MS (PPMS) is part of the spectrum of progressive MS and is likely not pathophysiologically distinct from relapsing MS that has entered a progressive course10
- On MRI, up to 42% of patients with PPMS (mean disease duration 3.3 years) have gadolinium-enhanced lesions13
- The diffuse meningeal inflammation in PPMS is associated with demyelinating pathology that contains B-cell infiltrates and is linked to severe clinical progression14
Disease activity results from B and T cells crossing the blood brain barrier (BBB) into the CNS
In normal homeostasis, immune cell access to the CNS is limited but not prevented by the BBB.15
In the formation of an MS lesion, autoreactive immune cells, including activated B and T cells, transit from the bloodstream to the CNS and proliferate following an interaction with a target self neuroantigen.15, 16
The hypercellularity around the blood vessel indicates cell proliferation and the breakdown of the BBB due to the release of inflammatory cytokines from these autoreactive cells.9,15,17
B cells can contribute to the pathophysiology of MS
Once inside the CNS, B cells have the capacity to influence the underlying pathophysiology of MS through several key roles.
Autoreactive B cells in the CNS present self-neuroantigens, which abnormally activate T cells and the T-cell proliferation response against neural tissue, resulting in autoimmunity4,6
B cells in patients with MS produce more proinflammatory cytokines than in people without the disease.18 This increased production results in reduced ability to regulate other immune responses18,19
Autoreactive B cells drive the production of autoantibodies against neural tissue, which contributes to injury.4 B-cell antibodies can also activate other immune calls, including macrophages and natural killer cells, to destroy tissue20
Ectopic lymphoid follicle-like aggregates:
In progressive MS, accumulation of B cells, T cells, and follicular dendritic cells can form in the meninges.21,22 Thee aggregates are linked to microglial activation, local inflammation, and neuronal loss in the nearby cortex
- 1. Prosperini L, et al. Eur J Neurol 2009;16(11):1202-9.
- 2. Deloire M, et al. Mult Scler 2010: 16(5):581-7.
- 3. Tremlett H, et al. Neurology 2009;73(20):1616-23.
- 4. Bar-Or A, Semin Neurol 2008;28(1):29-45.
- 5. Bruck W. J Neurol 2005;252(suppl 5):v3-9.
- 6. Ireland SJ, et al. Autoimmunity 2012;45(5):400-14.
- 7. Cepok S, et al. Brain 2005;128(pt 7):1667-76.
- 8. Frischer JM, et al. Brain 2005; 132(pt 5):1175-89.
- 9. Frohman EM, et al. N Engl J Med 2006;354(9):942-55.
- 10. Lublin FD, Reingold SC. Neurology 1996;46(4):907-11.
- 11. Sahraian MA, Eshagh A. Clin Neurol Neurosurg 2010;112(7):609-15.
- 12. Lublin FD, et al. Neurology 2014;83:1-9.
- 13. Ingle GT, et al. J Neurol Neurosurg Psychiatry 2005;76:1255-58.
- 14. Choi SR, et al. Brain 2012;135(pt 10)2925-37
- 15. Ortiz GG, et al. Arch Med Res 2014;45(8):687–97.
- 16. Hartung HP, et al. Handbook of Clinical Neurology. 2014;122(3rd series):3–14.
- 17. Palmer AM. Cardiovasc Psychiatry Neurol. 2013;2013:530356.
- 18. Bar-Or A, et al. Ann Neurol 2010;67(4):452–61.
- 19. Duddy M, et al. J Immunol 2007;178(10):6092–9
- 20. Weber MS, et al. Biochem Biophys Acta 2011;1812(2):239-45.
- 21. Serafini B, et al. Brain Pathol 2004;14(2):164–74.
- 22. Magliozzi R, et al. Ann Neurol 2010;68(4):477-93.
August 2016, NP/OCRE/1507/0020l(1)